Resources

News

Press release
November 6, 2026

KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial

Read more
Press release
August 19, 2026

KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing

Read more
Press release
November 19, 2025

KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors

Read more
Press release
October 1, 2025

KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors

Read more
Press release
May 20, 2025

KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors

Read more
Press release
March 25, 2025

KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting

Read more
Press release
November 18, 2024

KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates

Read more
Press release
October 8, 2024

KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors

Read more
Press release
September 4, 2024

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Read more
Press release
July 1, 2024

KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors

Read more
Press release
February 21, 2024

KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer

Read more
Press release
January 31, 2024

KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses

Read more
Press release
October 24, 2023

KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors

Read more
Press release
May 19, 2023

KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Read more
Press release
May 10, 2023

KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors

Read more
Press release
May 3, 2023

KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Read more
Press release
April 17, 2023

KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting

Read more
Press release
December 13, 2022

KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards

Read more
Press release
November 10, 2022

KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting

Read more
Press release
November 1, 2022

KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline

Read more
Press release
October 24, 2022

KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)

Read more
Press release
October 5, 2022

KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting

Read more
Press release
May 23, 2022

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

Read more
Press release
March 16, 2022

KaliVir Immunotherapeutics Closes Series A Financing

Read more
Press release
November 4, 2021

KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.

Read more
Press release
June 17, 2021

KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors

Read more
Press release
December 7, 2020

KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.

Read more
In the news
January 1, 2020

How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies

Read more